X4 Pharmaceuticals Announces Positive Top-Line Results From 4Whim Global, Pivotal Phase 3 Trial Of Once-Daily, Oral Mavorixafor In Whim Syndrome

Published on November 29, 2022 01:09 PM PST

Nov 29 (Reuters) - X4 Pharmaceuticals Inc:

* X4 PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM 4WHIM GLOBAL, PIVOTAL PHASE 3 TRIAL OF ONCE-DAILY, ORAL MAVORIXAFOR IN WHIM SYNDROME

* MAVORIXAFOR WAS GENERALLY WELL TOLERATED IN TRIAL

* 4WHIM MET ITS PRIMARY ENDPOINT, WITH MAVORIXAFOR ACHIEVING CLINICAL AND STATISTICAL SUPERIORITY OVER PLACEBO WHEN MEASURING TATANC

* 4WHIM MET KEY SECONDARY ENDPOINT, WITH MAVORIXAFOR ACHIEVING CLINICAL & STATISTICAL SUPERIORITY OVER PLACEBO WHEN MEASURING TATALC Source text for Eikon: Further company coverage:

Reuters

Reuters -
102386 Posts
...

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.